Taibang Biologic Group’s Privatization and Delisting from NASDAQ

JunHe advised a Financing Syndicate on the deal.

Taibang Biologic Group had signed a merger agreement with CBPO Holdings Limited and its wholly owned subsidiary, CBPO Group Limited. According to this agreement, Taibang Biologic will remain as an entity and be a wholly owned subsidiary company of CBPO Holdings Limited after the merger. The Company’s shares will then no longer be traded and start the delisting process from the NASDAQ. 

Taibang Biologic Group is an integrated Chinese blood product and biomedical company.

The consortium consisted of  Centurium Capital, CITIC Capital, Hillhouse Capital and Temasek, as well as some other well-known funds. The investors financed Taibang’s privatization through a combination of equities and debts. 

The leading partner of this project was Mr. Hui Zhou (Picture) and Mr. Yifeng Yuan. 

Involved fees earner: Hui Zhou – JunHe;

Law Firms: JunHe;

Clients: Centurium Capital; CITIC Capital; Hillhouse Capital Management; Temasek;

Author: Sonia Carcano